Genfit (GNFT)

4.26
+0.06(+1.43%)
  • Volume:
    117,144
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    4.16 - 4.26

GNFT Overview

Prev. Close
4.2
Day's Range
4.16-4.26
Revenue
94.29M
Open
4.2
52 wk Range
2.8-4.77
EPS
1
Volume
117,144
Market Cap
206.87M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
76,054
P/E Ratio
4.16
Beta
1.07
1-Year Change
22.09%
Shares Outstanding
49,655,468
Next Earnings Date
Apr 05, 2023
What is your sentiment on Genfit?
or
Market is currently closed. Voting is open during market hours.

Genfit News

Genfit Analysis

Genfit Company Profile

Genfit Company Profile

Employees
134
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0004163111

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Read More

Analyst Price Target

Average8.93 (+109.70% Upside)
High13.00
Low5.00
Price4.26
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyBuy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral
  • what's the reason of fall of Genfit?
    0
    • i also want to know
      0
    • dont worry it Will raise soon 😉
      1
  • it cheap to buy
    0
    • Trials for NASH will continue after dataset correction
      2
      • they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
        1
        • not all value but a drug development. they have so many programs to continue
          0
      • damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
        0
        • Whats the status , will it still go down ?
          0
          • Yes
            0
        • this baby Is the brother of contravirpharma (HEPA) .. same diseases.
          0
          • what do you mean?
            0
        • WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
          0
          • does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
            0
          • DATA is opn in 1Q 2019?
            0